Levocarnitine

Generic Name: Levocarnitine

Brand Names: Carnitor

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅NO_₃

CAS Number: 541-15-1

Unique Ingredient Identifier: 0G389FZZ9M

Background: Constituent of striated muscle and liver. It is used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias.

Indication: ⑴用于继发性肉碱缺乏症。主要用于慢性肾衰长期血透患者因肉碱缺乏产生的一系列并发症状，临床表现如心肌病、骨骼肌病、心律失常、高脂血症，以及低血压和透析中肌痉挛等。

⑵用于罕见病β-酮硫解酶缺乏症（BKD）和原发性肉碱缺乏症（PCD）。

⑶用于罕见病戊二酸Ⅰ型。

⑷用于维持罕见病同型半胱氨酸血症引起的血液游离肉碱的正常水平。

Associated Conditions: Carnitine Deficiency, Congenital carnitine deficiency, Secondary Carnitine deficiency

Associated Therapies: -

Clinical Trials

Effects of L-carnitine on Hypothyroidism

Phase 4

Completed

Conditions: Hypothyroidism

Interventions: Drug: L-carnitine
Drug: Placebo

First Posted Date: 2013-01-16

Last Posted Date: 2013-12-04

Lead Sponsor: Korea University Anam Hospital

Target Recruit Count: 60

Registration Number: NCT01769157

Locations: 🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of

Adding L-carnitine in Clomiphene Resistant Polycystic Ovary Improves the Quality of Ovulation and the Pregnancy Outcome

Phase 4

Conditions: Treatment Resistant Disorders

Interventions: Drug: l-carnitine

First Posted Date: 2012-08-15

Last Posted Date: 2013-09-10

Lead Sponsor: Woman's Health University Hospital, Egypt

Target Recruit Count: 157

Registration Number: NCT01665547

Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis

Phase 2

Conditions: Non-alcoholic Steatohepatitis

Interventions: Drug: Atorvastatin
Drug: Placebo
Drug: L-Carnitine

First Posted Date: 2012-06-12

Last Posted Date: 2018-05-11

Lead Sponsor: Tehran University of Medical Sciences

Target Recruit Count: 440

Registration Number: NCT01617772

Locations: 🇮🇷
Masoud Clinic, Tehran, Iran, Islamic Republic of
🇮🇷
Pars Cohort Center, Shiraz, Fars, Iran, Islamic Republic of

L-carnitine to Treat Fatigue Associated With Crohn's Disease

Not Applicable

Withdrawn

Conditions: Crohn's Disease
Fatigue

Interventions: Other: Placebo
Drug: L-carnitine

First Posted Date: 2012-02-01

Last Posted Date: 2014-01-17

Lead Sponsor: University of California, San Francisco

Registration Number: NCT01523106

Locations: 🇺🇸
UCSF Medical Center, Mt. Zion Medical Center, San Francisco, California, United States

Effect of Oral L-carnitine Supplement on Lipid Profile, Anemia, and Quality of Life of Patients

Phase 2

Completed

Conditions: Complication of Hemodialysis

Interventions: Drug: placebo
Drug: L-carnitine

First Posted Date: 2011-01-19

Last Posted Date: 2011-01-19

Lead Sponsor: Isfahan University of Medical Sciences

Target Recruit Count: 54

Registration Number: NCT01278693

Locations: 🇮🇷
Noor university hospital, Isfahan, Iran, Islamic Republic of

The Effects of L-carnitine on Fatigue in Spinal Cord Injury

Phase 2

Completed

Conditions: Spinal Cord Injury (SCI)

Interventions: Drug: L-Carnitine

First Posted Date: 2010-11-02

Last Posted Date: 2014-10-08

Lead Sponsor: University of British Columbia

Target Recruit Count: 2

Registration Number: NCT01232907

Locations: 🇨🇦
Rehab Research Lab, GF Strong Rehab Centre, 4255 Laurel Street, Vancouver, British Columbia, Canada

Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies.

Not Applicable

Completed

Conditions: Cirrhosis

Interventions: Drug: L-carnitine
Drug: Lactulose

First Posted Date: 2010-11-01

Last Posted Date: 2013-02-27

Lead Sponsor: University Hospital, Caen

Target Recruit Count: 55

Registration Number: NCT01231828

Locations: 🇫🇷
University Hospital of Caen, Caen, France

L-Carnitine Administration in Early Sepsis

Phase 1

Terminated

Conditions: Septic Shock

Interventions: Drug: L-Carnitine
Drug: Normal Saline

First Posted Date: 2010-09-02

Last Posted Date: 2022-04-22

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 31

Registration Number: NCT01193777

Locations: 🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸
Carolinas Medical Center, Charlotte, North Carolina, United States

Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis

Phase 3

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Placebo
Drug: L-Carnitine

First Posted Date: 2010-06-23

Last Posted Date: 2017-05-08

Lead Sponsor: University Hospital, Bordeaux

Target Recruit Count: 59

Registration Number: NCT01149525

Locations: 🇫🇷
University Hospital, Hospital Pasteur, Nice, France
🇫🇷
University Hospital, Hospital Laënnec, Nantes, France
🇫🇷
University Hospital, Hospital Pellegrin, Bordeaux, France

and more 3 locations

Vitamin C for Prophylaxis of Post-operative Atrial Fibrillation in On-pump Cardiac Surgery Procedures

Phase 3

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: L-Carnitine
Drug: Placebo
Drug: Vitamin C

First Posted Date: 2010-04-21

Last Posted Date: 2015-10-19

Lead Sponsor: Attikon Hospital

Target Recruit Count: 33

Registration Number: NCT01107730

Locations: 🇬🇷
University General Hospital Attikon, Athens, Greece

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy